Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: Theory and practice

Journal of Clinical Hypertension

Volumn 3, Issue 6, 2001, Pages 383-387

  Sica, D A ^a   Elliott, W J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; PLACEBO; VALSARTAN;

ARTICLE; CLINICAL OBSERVATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG CHOICE; DRUG CLASSIFICATION; HUMAN; HYPERTENSION; MEDICAL LITERATURE;

EID: 0035207490     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2001.00678.x     Document Type: Article

References (45)

1. Therapeutic trials comparing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
2. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
3. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
4. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
5. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
6. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
7. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
8. Effects of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: The Valsartan Heart Failure Trial (Val-HeFT)
9. Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure
10. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs
11. Additive effects of losartan and enalapril on blood pressure and plasma active renin
12. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients
13. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial
14. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension
15. Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension
16. Add-on angiotensin receptor blockade with maximized ACE inhibition
17. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis
18. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
19. Additive antiproteinuric effect of a converting-enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
20. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
21. IgA nephropathy and inhibitors of the renin angiotensin system: Is reduction in proteinuria adequate proof of efficacy?
22. Safety of the combination of valsartan and benazepril in patients with chronic renal disease
23. Angiotensin-converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: Either or both for primary renal disease?
24. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy
25. Angiotensin-II receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors in heart failure
26. Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?
27. Comparison of candesartan, enalapril, and their combination in congestive heart failure
28. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure
29. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin-converting enzyme inhibitor therapy in patients with heart failure
30. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects
31. The Randomized Angiotensin receptor Antagonist-ACE inhibitor Study (RAAS)-pilot study
32. Angiotensin II receptor blockade combined with ACE-inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure
33. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
34. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure
35. Pharmacology and clinical efficacy of angiotensin-receptor blockers
36. Angiotensin-converting enzyme inhibitors
37. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure
38. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade
39. Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations
40. Angiotensin converting enzyme and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease
41. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans
42. T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans
43. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients
44. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
45. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure